# A Phase I Study Of Oral Topotecan And Lapatinib In Subjects With Advanced Solid Tumors

> **NCT00682279** · PHASE1 · WITHDRAWN · sponsor: **GlaxoSmithKline**

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** oral topotecan (SK&F-104864); lapatinib (GW572016)

## Key facts

- **NCT ID:** NCT00682279
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-09
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Cancelled before enrollment
- **Last updated:** 2015-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00682279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00682279, "A Phase I Study Of Oral Topotecan And Lapatinib In Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00682279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*